Work on Senolytic Rejuvenation Therapies Begins to Attract More Mainstream Notice

This popular science piece on the development of senolytic therapies capable of clearing harmful senescent cells from aging tissues is a cut above the average. It is important to see more publicity for this line of work. Not because it will aid the industry, but because the more attention that is given to the field, the faster that existing senolytic treatments such as the dasatinib and quercetin combination will become available through off-label prescription and physician networks. Tens of millions of patients with inflammatory age-related diseases caused in part by senescent cells, and the many cancer survivors with high burdens of senescent cells due to chemotherapy, and diabetics whose condition is mediated by senescent cells, and the obese whose visceral fat tissue spurs cellular senescence might benefit in the US alone, if they only knew that senolytics exist today. The choice on whether to try now or wait for more human data for dasatinib and quercetin (or fisetin, or piperlongumine, or other easily obtained senolytics) should be one that people are permitted to make, not one they remain ignorant of because nobody bothered to tell them that it exists. My one complaint about the content of this article is that the author does conspicuously fail to mention that it is possible to obtain access to the first senolytic treatments today, at very low cost, and that older people in the self-experimentation community are indeed choosing to do this. Imagine if in...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs